These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1885750)

  • 21. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].
    Meng ZY; Zhang JY; Zhang ZG; Luo D; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1636-1641. PubMed ID: 30572392
    [No Abstract]   [Full Text] [Related]  

  • 22. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay J; Fonseca K; Charest H; Krajden M; Petric M; Mahmud SM; Van Caeseele P; Bastien N; Eshaghi A; Li Y
    J Infect Dis; 2015 Sep; 212(5):726-39. PubMed ID: 25784728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.
    Muñoz IS; Rello SR; Lejarazu RO
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Nov; 36(9):572-575. PubMed ID: 29179984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
    Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
    J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages.
    Pyhälä R; Kleemola M; Kumpulainen V; Vartiainen E; Lappi S; Pönkä A; Cantell K
    Vaccine; 1992; 10(9):631-6. PubMed ID: 1502842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
    Moser MJ; Hatta Y; Gabaglia C; Sanchez A; Dias P; Sarawar S; Kawaoka Y; Hatta M; Neumann G; Bilsel P
    Vaccine; 2019 Jul; 37(32):4533-4542. PubMed ID: 31280945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata.
    Skowronski DM; Hottes TS; De Serres G; Ward BJ; Janjua NZ; Sabaiduc S; Chan T; Petric M
    Pediatr Infect Dis J; 2011 Oct; 30(10):833-9. PubMed ID: 21857263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y
    J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vaccination against influenza in the elderly. Experience with adjuvant vaccines].
    Baldo V; Menegon T; Buoro S; Scalici C; Vesco A; Perale S; Boato W; Carletti M; Bonello C; Dalla Costa D; Trivello R
    Ann Ig; 1999; 11(5):369-74. PubMed ID: 10596424
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluating the case for trivalent or quadrivalent influenza vaccines.
    Baxter D
    Hum Vaccin Immunother; 2016 Oct; 12(10):2712-2717. PubMed ID: 27435025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
    Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
    PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.
    van de Sandt CE; Dou Y; Vogelzang-van Trierum SE; Westgeest KB; Pronk MR; Osterhaus ADME; Fouchier RAM; Rimmelzwaan GF; Hillaire MLB
    J Gen Virol; 2015 Aug; 96(8):2061-2073. PubMed ID: 25900135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity.
    Virk RK; Jayakumar J; Mendenhall IH; Moorthy M; Lam P; Linster M; Lim J; Lin C; Oon LLE; Lee HK; Koay ESC; Vijaykrishna D; Smith GJD; Su YCF
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):619-628. PubMed ID: 31843889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
    Kositanont U; Wongsurakiat P; Pooruk P; Maranetra N; Puthavathana P
    Viral Immunol; 2010 Jun; 23(3):329-34. PubMed ID: 20565296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects for broadly protective influenza vaccines.
    Treanor JJ
    Vaccine; 2015 Nov; 33 Suppl 4():D39-45. PubMed ID: 26338145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.